Free Trial
LON:POLB

Poolbeg Pharma (POLB) Share Price, News & Analysis

Poolbeg Pharma logo
GBX 4.98 -0.02 (-0.36%)
As of 04:52 AM Eastern

About Poolbeg Pharma Stock (LON:POLB)

Key Stats

Today's Range
4.98
5.30
50-Day Range
3.90
9.10
52-Week Range
3.55
15.77
Volume
1.85 million shs
Average Volume
9.91 million shs
Market Capitalization
£24.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt’s success and generating near term revenues. Poolbeg’s clinical programmes target large addressable markets including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality data to support partnering and further development. Its AI-led discovery programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.

Receive POLB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Poolbeg Pharma and its competitors with MarketBeat's FREE daily newsletter.

POLB Stock News Headlines

I was wrong. Dead wrong.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Hookipa Pharma to acquire Poolbeg Pharma
Poolbeg Pharma’s POLB 001 Shows Promise in CRS Treatment
Poolbeg Pharma Share Chat (POLB)
See More Headlines

POLB Stock Analysis - Frequently Asked Questions

Poolbeg Pharma's stock was trading at GBX 7.10 at the start of the year. Since then, POLB shares have decreased by 30.4% and is now trading at GBX 4.94.
View the best growth stocks for 2025 here
.

Shares of POLB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Poolbeg Pharma investors own include EQTEC (EQT), Great Western Mining (GWMO), Power Metal Resources (POW), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), Alzamend Neuro (ALZN) and Alpine 4 (ALPP).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
£-4,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 2.35 per share
Book Value
GBX 3 per share

Miscellaneous

Free Float
N/A
Market Cap
£24.71 million
Optionable
Not Optionable
Beta
2.11
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (LON:POLB) was last updated on 1/15/2025 by MarketBeat.com Staff
From Our Partners